PRESS RELEASE

Exhibit 99.1


THE TREATMENT OF H5N1 AVIAN INFLUENZA REPORT: RELEASED BY AETHLON MEDICAL
Wednesday March 15, 4:05 pm ET

SAN DIEGO--(BUSINESS WIRE)--March 15, 2006--Aethlon Medical, Inc. (OTCBB:AEMD
- -News), a pioneer in developing therapeutic devices for infectious disease,
disclosed this afternoon that Chairman and CEO, James A. Joyce, has authored a
report entitled; The Treatment of H5N1 Avian Influenza. The content of the
report follows:

Summary

The intent of this paper is to analyze how current options for treating H5N1
Avian Flu infection may influence the commercialization of the Aethlon
Hemopurifier(TM), a therapeutic device targeted to modulate the immune response
and capture circulating H5N1 virus. In the face of an accelerating pandemic, the
present void in effective H5N1 treatments may dictate that the Hemopurifier(TM),
initially proposed as a treatment for drug resistant patients, evolves into an
important first-line treatment role. Mounting evidence explaining why H5N1 is
often fatal to those infected with the virus reinforces the opportunity of the
Hemopurifier(TM) as an essential weapon in the treatment arsenal against Avian
Flu.

The Threat

Scientists are increasingly worried that the H5N1 strain of Avian Flu will
mutate into a form easily passed between humans, triggering a global pandemic.
It already is unprecedented as an animal illness in its rapid expansion, and has
cost 300 million farmers more than $10 billion during its initial spread through
poultry around the world. World Health Organization (WHO) officials claim the
H5N1 strain of Avian Flu poses a greater challenge to the world than any other
infectious disease, including AIDS. WHO officials confirm that 101 of 180 people
have died H5N1 infection as of March 15(h), 2006.

In the face of such dire news, researchers are unraveling the mystery of why the
H5N1 strain of the Avian Flu virus is so lethal. It appears that H5N1
hyper-activates the immune response, a frightening trait inherent in the worst
pandemic killer known to man, the Spanish Flu of 1918, which caused the deaths
of over 40 million people. To provide perspective, it has taken 25 years for
AIDS related deaths to rise to such levels. In the case of H5N1 infection, viral
sepsis leading to major organ failure is often the cause of death. This is
triggered when the immune system over-responds to infection by releasing a
cascade of inflammatory cells and chemicals in what is known as a "Cytokine
Storm". As a result, the likelihood of death in individuals with robust immune
systems equals or exceeds the immune compromised who are normally most
susceptible to regular seasonal flu strains. Unfortunately, antiviral drugs are
unable to shut off a cytokine storm once it has been triggered.

Current Treatments

Antiviral drugs being stockpiled as part of a global strategy to treat Avian Flu
have no therapeutic value once the cytokine storm has been triggered. At
present, only one antiviral, oseltamivir (Tamiflu) is known to offer some level
of effectiveness against the H5N1 strain of Avian Flu. However, Tamiflu is
indicated as a treatment for normal household varieties of influenza if
administered within 48 hours of first symptoms. The treatment window for an
ultra-virulent H5N1 strain is likely to narrow considerably. Reports already
indicate the potency of Tamiflu against the avian flu virus is reduced, even
when taken after 24 hours of the first symptoms of the disease. H5N1 resistance
to Tamiflu is already being reported in Southeast Asia.

Prolonged incubation combined with a short antiviral treatment window also
concerns researchers. Dr. Tim Uyeki, a medical epidemiologist with the influenza
branch of the Centers for Disease Control and Prevention (CDC) quoted the
following to the Wall Street Journal; "Patients aren't presenting (symptoms)
early in the illness. If the cytokine storm has already been triggered,
antiviral drugs aren't going to turn it off."

A successful global strategy against H5N1 will, at a minimum, have to rely on
therapeutics that can modulate the overproduction of cytokines. The March 2,
2006 issue of The Lancet reported that researchers at the well-regarded
Karolinska Institute in Stockholm are proposing the use of chemotherapy to kill
off excess immune cells as a means to curb the cytokine storm leading to viral
sepsis in H5N1 patients. While the concept may seem radical, researchers are
likely to agree that any treatment able to damp down the immune system might be
helpful. Unfortunately, taming the immune system without destroying defenses
against infection has yet to be demonstrated with drugs.


Until other treatments surface, health officials from the United States and
other nations continue a strategy of stockpiling Tamiflu. To date, the
Department of Health and Human Services (HHS) has ordered 12.4 million doses of
Tamiflu, and expects to have a stockpile of 20 million doses by the end of 2006.
Adjunctive antiviral therapies able to increase Tamiflu effectiveness will need
to surface if these stockpiles are to offer any hope of widespread benefit.
Regardless, the effectiveness of Tamiflu and other antiviral drugs ends once the
cytokine cascade is triggered.

The Hemopurifier(TM) to Treat Avian Flu

The Hemopurifier(TM) is presently the only proposed treatment for H5N1 Avian Flu
that simultaneously targets the clearance of H5N1 and the modulation of the
cytokine storm. The deployment of the Hemopurifier(TM) as a treatment for Avian
Flu is consistent with a corporate strategy to evolve the Hemopurifier as a
broad-spectrum treatment for drug and vaccine resistant pathogens. In this
context, the Hemopurifier(TM) was recently awarded the 2006 Technology
Innovation Award by global industry researcher, Frost & Sullivan. Specific to
H5N1 infection, the Hemopurifier(TM) represents a novel extracorporeal method to
mimic and boost the immune response, which should improve the effectiveness of
antiviral drugs when deployed as an adjunctive therapy. Once a cytokine storm
has been triggered, the Hemopurifier could serve as the first and perhaps only
option for treating H5N1 infected patients. Attributes and considerations for
deploying the Hemopurifier(TM) as a treatment for pandemic flu, include:

1. Rapid Clearance of H5N1 -The affinity agents immobilizedwithin
the Hemopurifier(TM) have broad-spectrum capabilities
tocapture envelope viruses by binding to glycosolated proteins
that reside on their surface. In the case of H5N1, the virus
capture is directed at two major surface glycoproteins, the
hemagglutinin (HA) and neuraminidase (NA), which are
availablebinding sites, even in the case of viral mutation. As
comparedto normal influenza, longer periods of incubation and
accessibility to circulating virus appear to be the norm in
H5N1 infection. The ability to clear H5N1 virus and viral
fragments prior to cell and organ infection, would
decreasecytokine production, inhibit disease progression, and
improvethe effectiveness of Tamiflu and other antiviral drugs.

2. Broad Clearance of Cytokines - The structure of
theHemopurifier(TM) vastly improves the potential to clear the
full spectrum of deleterious cytokines, as compared to
Hemofiltration techniques indicated as an adjunct treatment
forcytokine induced sepsis since 1990. In fact, the
Hemopurifier(TM) may be an ideal method to modulate cytokine
production, as the pores of the Hemopurifier(TM) fibers are
large enough to allow both cytokines and cytokine aggregates,
unable to be cleared in Hemofiltration, to be separated and
captured from circulation. Non-human studies to document the
capture of cytokines, prevalent in autopsy reports of H5N1
induced deaths, have been initiated by Aethlon researchers.

3. Expedited Regulatory Path -Under the Bioterrorism Act of
2002,pandemic flu therapies can be developed and financed by
the Project BioShield Act. The guidelines require clinical
trials to only demonstrate safety in man, as traditional
efficacy studies are not plausible or ethical in the case with
pathogenic influenza. Thus, the FDA is permitted to accept
efficacy data from animal models related to drug and vaccine
submissions. In the absence of an animal model, the
Hemopurifier(TM) is positioned to demonstrate the capture of
viruses and cytokines from human blood through closed loop
studies that replicate human treatment. An Avian Flu Industry
Report published by Griffin Securities, suggests that these
regulatory provisions not only provide an accelerated path to
approval, but could also provide government funding for
stockpiling, representing large commercial opportunities for
companies developing Avian Flu therapies.

4. Human Safety Observations - H5N1 Avian Flu is not a call
toarms to initiate drug and vaccine research programs. It's a
siren to deliver therapeutics that are in late stage
development and can be delivered to market. The proposed
treatment of H5N1 with the Aethlon Hemopurifier(TM) would be
based on treatment protocols already established in a human
safety study currently being administered to renal failure
patients co-infected with the Hepatitis-C virus. To date, no
material adverse events have been observed in these
patients.Upon completion of this study, Aethlon will submit
the safety data as part of regulatory submissions to the Food
and Drug Administration (FDA) in an effort to pursue the
treatment of H5N1 Avian Flu and other drug and vaccine
resistant viral conditions. The Company may also seek to
commercialize the Hemopurifier(TM) through regulatory agencies
outside of the United States.

2

In closing, the ominous threat of an H5N1 pandemic; the absence of a vaccine; an
evolving resistance to a single drug option; and, a post-infection immune
response that triggers a highly fatal cytokine storm; provides organizations
with innovative therapeutics, the opportunity to demonstrate effectiveness on a
global stage. Those who execute and deliver therapeutics to the market will play
an important role in saving the lives of individuals infected with H5N1 pandemic
influenza.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat infectious
disease. The device, known as the Hemopurifier(TM), is a broad-spectrum
treatment countermeasure against drug and vaccine resistant bioweapons,
naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic
infectious disease targets including Hepatitis-C (HCV) and the Human
Immunodeficiency Virus (HIV). Aethlon has also initiated research on a second
generation Hemopurifier(TM) that targets the capture of growth factors inherent
in the spread of Cancer. More information on Aethlon Medical and the
Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to raise
capital when needed, the Company's ability to complete the development of its
planned products, the ability of the Company to obtain FDA and other regulatory
approvals permitting the sale of its products, the Company's ability to
manufacture its products and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, product
liability exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results could differ
materially as a result of a variety of factors, including the risks associated
with the effect of changing economic conditions and other risk factors detailed
in the Company's Securities and Exchange Commission filings.


Contact:

Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800 x302
jrichardson@aethlonmedical.com
- ------------------------------

or
James A. Joyce, 858-459-7800 x301
jj@aethlonmedical.com
- ---------------------


3